Haloperidol decanoate impurities

Manus Aktteva Biopharma LLP, an ISO 9001: 2008 certified sourcing & export concern takes pride in fulfilling your requirements of Nutraceuticals, Specialty Chemicals, Pharmaceutical APIs and their advance level intermediates from ISO Certified, GMP, CGMP & USFDA approved units with supportive regulatory documentations like DMF, EDMF, COS, USDMF etc. We wish to state that anyone interested in sourcing any special molecules, APIs, Intermediates, Chiral Compounds etc. and feels it is difficult for early completion of tasks, please call on us and TEST US TO GET THE BEST OF US.

Haloperidol (Haldol) is the most studied agent for the treatment of delirium in adult ICU patients. It is a neuroleptic agent that binds to postsynaptic dopamine receptors and has strong central antidopaminergic activity. All patients should be monitored closely for extrapyramidal side effects, neuroleptic malignant syndrome, and QT prolongation, which may lead to torsades de pointes. Appropriate Haldol dosing in ICU patients is to administer doubling doses every 15–20 minutes until the patient responds, at which point the total dose administered should be divided and administered in 6-hour intervals. Some anecdotal experience and limited studies suggest that newer second-generation neuroleptics such as olanzapine and quetiapine may be as effective as haloperidol with a more beneficial adverse effect profile.

Haloperidol decanoate impurities

haloperidol decanoate impurities


haloperidol decanoate impuritieshaloperidol decanoate impuritieshaloperidol decanoate impuritieshaloperidol decanoate impuritieshaloperidol decanoate impurities